logo-loader
Health
CytoDyn

Full interview: CytoDyn looks to FDA to green light Phase 2 trials of leronlimab to treat colon cancer

CytoDyn Inc (OTCMKTS:CYDY) CEO Dr Nader Pourhassan tells Proactive the biotech has filed a Phase 2 protocol with the Food and Drug Administration for a combination therapy of leronlimab and regorafenib to treat patients with metastatic colorectal cancer.

Dr Pourhassan explains that the Vancouver, Washington-based biotechnology company's animal studies with this indication show "strong results" so there is no reason why CytoDyn should not progress to Phase 2 trials.

Quick facts: CytoDyn

Price: $0.43

Market: OTCQB
Market Cap: $162.01 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment...

FOR OUR FULL DISCLAIMER CLICK HERE

More on this story

Watch

Full interview: Rockfire Resources' David Price discusses Brigalow Alluvial...

Rockfire Resources PLC's (LON:ROCK) David Price tells Proactive London's Andrew Scott they've been getting a better understanding of an alluvial gold deposit next one of their main assets in Queensland. Calculations made in 1986 on an area known as Brigalow Alluvial Goldfield has suggested...

2 days, 17 hours ago

2 min read